Core Scientific Inctx
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
CORZ$13.13+3.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Deficit (Unaudited)
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
For the Three Months Ended March 31, 2025
| Common Stock · AdditionalPaid-In Capital · AccumulatedDeficit · TotalStockholders’(Deficit) Equity | |||||
|---|---|---|---|---|---|
| Shares · Amount | |||||
| Balance at December 31, 2024 | 292,606 | 3 | 2,915,035 | (3,735,218) | (820,180) |
| Net income | — | — | — | 580,693 | 580,693 |
| Stock-based compensation | — | — | 16,405 | — | 16,405 |
| Restricted stock awards issued, net of shares withheld for tax withholding obligations | 2,981 | — | (50) | — | (50) |
| Exercise of warrants | 3,500 | $— | 41,625 | — | 41,625 |
| Balance at March 31, 2025 | 299,087 | $3 | $2,973,015 | $(3,154,525) | $(181,507) |
Condensed Consolidated Statements of Changes in Stockholders’ Deficit
For the Three Months Ended March 31, 2024
| Common Stock · AdditionalPaid-In Capital · AccumulatedDeficit · TotalStockholders’Deficit | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||
| Balance at December 31, 2023 | 386,883 | $36 | $1,823,260 | $(2,420,237) | $(596,941) | ||||
| Cumulative effect of adoption of ASU 2023-08, Accounting for and Disclosure of Crypto Assets | — | — | — | 24 | 24 | ||||
| Balance at December 31, 2023, adjusted | 386,883 | 36 | 1,823,260 | (2,420,213) | (596,917) | ||||
| Net income | — | — | — | 210,691 | 210,691 | ||||
| Stock-based compensation | — | — | (1,060) | — | (1,060) | ||||
| Cancellation of common stock in connection with emergence | (386,883) | (36) | 36 | — | — | ||||
| Issuance of new common stock in connection with emergence | 152,497 | 2 | 296,494 | — | 296,496 | ||||
| Issuance of new common stock under the Equity Rights Offering | 15,649 | — | 55,000 | — | 55,000 | ||||
| Issuance of new common stock for the Equity Rights Offering backstop commitment | 2,111 | — | 5,475 | — | 5,475 | ||||
| Issuance of new common stock for Bitmain obligation | 10,735 | — | 27,839 | — | 27,839 | ||||
| Conversion premium on the issuance of the New Secured Convertible Notes | — | — | 33,202 | — | 33,202 | ||||
| Issuance of warrants | — | — | (345,856) | — | (345,856) | ||||
| Exercise of stock options | — | 9 | — | 9 | |||||
| Restricted stock awards issued, net of tax withholding obligations | 1,285 | — | (3,388) | — | (3,388) | ||||
| Restricted stock awards forfeited | (40) | — | — | — | — | ||||
| Balance at March 31, 2024 | 182,237 | $2 | $1,891,011 | $(2,209,522) | $(318,509) | ||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.